Adjusted Revenue

Adjusted Revenue %Chg

Adjusted Gross Profit

Adjusted Gross Profit %Chg

Adjusted Gross Margin

Adjusted Gross Margin %Chg

Adjusted EBIT

Adjusted EBIT %Chg

Adjusted EBIT Margin

Adjusted EBIT Margin %Chg

Adjusted EBITDA

Adjusted EBITDA %Chg

Adjusted EBITDA Margin

Adjusted EBITDA Margin %Chg

Adjusted Net Income

Adjusted Net Income %Chg

Adjusted Net Income Margin

Adjusted Net Income Margin %Chg

Adjusted EPS

Adjusted EPS %Chg

Adjusted Free Cash Flow (FCF)

Adjusted Free Cash Flow (FCF) %Chg

Adjusted Free Cash Flow Margin

Adjusted Free Cash Flow Margin %Chg

Adjusted Capital Expenditures

Adjusted Capital Expenditures %Chg

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.

Metric	Dec '27 (E)	Dec '26 (E)	Dec '25 (E)	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20
Adjusted Revenue			2,511.1
Adjusted Gross Profit			—
Adjusted Gross Margin			—
Adjusted EBIT			527.4
Adjusted EBIT Margin			21%
Adjusted EBITDA			552.5
Adjusted EBITDA Margin			22%
Adjusted Net Income			436.3
Adjusted Net Income Margin			17.4%
Adjusted EPS			14.8
Adjusted Free Cash Flow (FCF)			665.7
Adjusted Free Cash Flow Margin			26.5%
Adjusted Capital Expenditures			-39.5